The recent release of the Fed’s survey brought Bitcoin 
$75,226‘s (BTC) price below $102,000, with a temporary low possibly being established around $101,800. The survey highlighted weak credit demand in the first quarter, reflecting concerns over consumer spending and indicating potential negative economic signals. Despite this, the markets buzz with optimism due to improvements in U.S.-China relations. What do the forecasts suggest for AVAX, PEPE, and Pi Coin this week?
AVAX Price Forecast
Following BTC’s rally, altcoins have shown significant double-digit gains, but the upward momentum of BTC has stalled, failing to overcome the resistance at $105,000. Investors are approaching altcoins with caution, considering the potential for renewed regulatory challenges and the impending ‘sell and go away’ period that typically marks the end of May. As a result, many remain wary of sudden market shifts.
AVAX tested the $27 level as anticipated but failed to maintain its position above it. Market expectations lean towards a retreat to $22.5. If BTC does not hit new highs and investor caution persists, a dip back to the $23-$22.5 range is likely.
In a bullish scenario, the $27.3 region would be retested, with $34.7 as a new target. This will largely depend on the forthcoming Consumer Price Index (CPI) data.
Pepe Coin Insights
As predicted for PEPE Coin, a sharp rise in ETH prices triggered significant gains in PEPE Coin value, though the price couldn’t surpass the $0.0000155 resistance after a 95% increase. In a potential decline, the market anticipates a drop back to $0.0000113.
Last July, the $0.0000127 area was crucial for an upward threshold, maintaining potential targets between $0.0000168 and $0.0000218 if not breached. ETH’s performance will be pivotal in sustaining this growth potential.
Pi Coin Price Prediction
Approaching mid-month, sudden spikes in Pi Coin’s price have been anticipated. Testing the $1.67 mark wasn’t unexpected. However, ongoing challenges persist due to constant concerns about supply uncertainty and transparency, often considered overpriced, leading to significant upper wicks in price charts.
The psychological support at $1 remains intact, and if $1.3 is exceeded again, trials aiming toward $2 could still appear on the horizon.
